Zoledronic acid 5mg solution for infusion (Aclasta® ) contraindicated in patients with severe renal impairment with creatine clearance < 35mL/min

Novartis (Singapore) Pte Ltd issued a Dear Healthcare Professional Letter to inform healthcare professionals of important safety information regarding Aclasta® (zoledronic acid). From postmarketing surveillance, cases of acute renal failure requiring hospitalisation and/or dialysis or fatal outcome have been observed in patients with underlying moderate to severe renal impairment or with other risk factors. Hence, Aclasta® is now contraindicated in patients with severe renal impairment with creatinine clearance < 35 mL/min. Please refer to the Dear Healthcare Professional Letter for more details on the important considerations regarding renal adverse events associated with use of Aclasta®.
Healthcare professional
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.